Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01549964 · ClinicalTrials.gov registry record · Phase 3
Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Takeda.
- Terminated
- Registry status
- Phase 3
- Development phase
- 916
- Enrollment target
NCT01549964 is a Phase 3 study that was terminated before completion, run by Takeda. The registered enrollment target is 916 participants.
The verdict
NCT01549964, a Phase 3 study, was terminated before completion, sponsored by Takeda.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 916 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
Interventions
- DRUG Placebo
- DRUG Sitagliptin
- DRUG Fasiglifam (TAK-875)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 916 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01549964
The ClinicalTrials.gov registry entry for NCT01549964 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 916 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01549964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01549964 about?
NCT01549964 is a clinical study titled "Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes". The purpose of this study is to evaluate the efficacy of 2 doses of TAK-875 (25 mg and 50 mg), once daily (QD), plus metformin compared to placebo plus metformin and sitagliptin plus metformin on lowering blood sugar.
What is the current status of trial NCT01549964?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 916 participants. The study started on 2012-04. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01549964?
The interventions under investigation include: Placebo (DRUG), Sitagliptin (DRUG), Fasiglifam (TAK-875) (DRUG).
Who is sponsoring clinical trial NCT01549964?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.